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Motion sickness occurs under a variety of circumstances and is common in the general
population. It is usually associated with changes in gastric motility, and hypothermia,
which are argued to be surrogate markers for nausea; there are also reports that
respiratory function is affected. As laboratory rodents are incapable of vomiting,
Suncus murinus was used to model motion sickness and to investigate changes in
gastric myoelectric activity (GMA) and temperature homeostasis using radiotelemetry,
whilst also simultaneously investigating changes in respiratory function using whole
body plethysmography. The anti-emetic potential of the highly selective histamine H1
receptor antagonists, mepyramine (brain penetrant), and cetirizine (non-brain penetrant),
along with the muscarinic receptor antagonist, scopolamine, were investigated in the
present study. On isolated ileal segments from Suncus murinus, both mepyramine
and cetirizine non-competitively antagonized the contractile action of histamine with
pKb values of 7.5 and 8.4, respectively; scopolamine competitively antagonized the
contractile action of acetylcholine with pA2 of 9.5. In responding animals, motion
(1Hz, 4 cm horizontal displacement, 10 min) increased the percentage of the power of
bradygastria, and decreased the percentage power of normogastria whilst also causing
hypothermia. Animals also exhibited an increase in respiratory rate and a reduction
in tidal volume. Mepyramine (50 mg/kg, i.p.) and scopolamine (10 mg/kg, i.p.), but
not cetirizine (10 mg/kg, i.p.), significantly antagonized motion-induced emesis but did
not reverse the motion-induced disruptions of GMA, or hypothermia, or effects on
respiration. Burst analysis of plethysmographic-derived waveforms showed mepyramine
also had increased the inter-retch+vomit frequency, and emetic episode duration.
Immunohistochemistry demonstrated that motion alone did not induce c-fos expression
in the brain. Paradoxically, mepyramine increased c-fos in brain areas regulating emesis
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control, and caused hypothermia; it also appeared to cause sedation and reduced
the dominant frequency of slow waves. In conclusion, motion-induced emesis was
associated with a disruption of GMA, respiration, and hypothermia. Mepyramine was a
more efficacious anti-emetic than cetirizine, suggesting an important role of centrally-
located H1 receptors. The ability of mepyramine to elevate c-fos provides a new
perspective on how H1 receptors are involved in mechanisms of emesis control.
Keywords: gastric myoelectric activity, histamine H1 receptors, hypothermia, motion sickness, muscarinic
receptors, respiration pattern, Suncus murinus
INTRODUCTION
Motion sickness, also known as kinetosis and travel sickness, is
a common but complex syndrome which is characterized by a
cluster of signs and symptoms including cold sweating, facial
pallor, drowsiness, hypersalivation, “stomach awareness”, and
nausea and vomiting (Golding and Gresty, 2015). Symptomology
is very inter-individual variable (Sharma, 1997; Golding, 2006;
Murdin et al., 2011) and there is no standardized method of
assessment (Shupak and Gordon, 2006; Murdin et al., 2011).
The most widely accepted mechanism of motion sickness is the
“sensory-mismatch theory” which proposes motion-generated
sensory conflict and neural mismatch between converging
vestibular, visual and proprioceptive input patterns, that are
different from learned and expected sensory patterns (Reason
and Brand, 1975; Reason, 1978); for a discussion of other theories
or modifications of the “sensory-mismatch theory” (see Oman,
2012; Oman and Cullen, 2014; Bertolini and Straumann, 2016).
Irrespective of how sensory mismatch occurs, our understanding
of how conflicted signal activate the pathways responsible
for the induction of nausea and vomiting and accompanying
physiological response, particularly in the stomach, is not well
defined (Yates et al., 2014).
Two main classes of drug, anticholinergics (e.g., scopolamine)
and antihistamines (e.g., promethazine) are the most common
treatments for motion sickness (Schmäl, 2013; Golding and
Gresty, 2015). However, these types of agents are variably
efficacious in motion sickness and are associated with unwanted
side effects including sedation, drowsiness, blurred vision,
depression, and dry mouth/nose/throat (Spinks and Wasiak,
2011; Schmäl, 2013). Furthermore, the efficacy of all existing
anti-motion sickness drugs is quite modest. The antihistamines
used in humans to treat motion sickness are brain penetrant
and are also weak muscarinic receptor antagonists (Simon and
Simons, 2008; Schmäl, 2013). Compounds that do not penetrate
the blood brain barrier have also been examined for their anti-
motion sickness potential in humans. For example, the non-
brain penetrant H1 receptor antagonist, terfenadine, possessing
affinity for H1 receptor (IC50 = 6 nM) (Benavides et al., 1995),
suppressed motion-induced nausea and autonomic dysfunction
(Kohl et al., 1991). However, other non-brain penetrant
compounds such as cetirizine and fexofenadine (the active
metabolite of terfenadine) failed to prevent motion sickness,
although their side effect profiles were not documented (Cheung
et al., 2003). In these clinical studies, the motion sickness-
rating scores were related to “nausea” and not “vomiting.” It
remains unknown, therefore, whether highly selective, non-
brain penetrant histamine H1 receptor antagonists are able to
affect vomiting, as opposed to nausea or associated physiological
changes, in the absence of undesirable side effects.
Suncus murinus (house musk shrew) is an insectivore used
to study mechanisms of motion-induced emesis in which brain
penetrant older-generation histamine H1receptor antagonists
and themuscarinic receptor antagonist scopolamine have efficacy
(Ueno et al., 1988). Supporting evidence for involvement of
histamine in emesis comes from investigations showing an
induction of emesis by histamine (Bhargava and Dixit, 1968)
and the presence of histamine and acetylcholine receptors
in the vestibular system (for reviews see, Matsuoka et al.,
1983; Soto and Vega, 2010). In the present studies, therefore,
we used Suncus murinus to elucidate the potential of the
non-brain penetrant H1 receptor antagonist, cetirizine (Chen,
2008), to antagonize motion-induced emesis in comparison with
the brain penetrant, highly selective H1 receptor antagonist,
mepyramine (Fitzsimons et al., 2004); scopolamine was used as a
positive control (Nakayama et al., 2005). These experiments were
performed in animals implanted with radiotelemetry devices to
permit recording of the gastric myoelectric activity (GMA) and
body temperature, since alteration of gastric slow waves and
hypothermia has been associated with motion-induced nausea
in humans (Stern et al., 1987; Nalivaiko et al., 2015). We also
recorded respiratory function, which is also disturbed during
nausea and interrupted during emesis (Cowings et al., 1986;
Himi et al., 2004; Gavgani et al., 2016; Horn et al., 2016). The
collection of physiological data in Suncus murinus was also done
in conjunction with an assessment of behavior to quantify side
effects and to provide an insight into behaviors that collectively
may be indicative of “nausea” (Horn et al., 2011, 2013). At
the end of the experiments, brains were processed for c-fos
immunohistochemistry to identify which central pathways were
activated by motion stimulus. Suncus murinus is not a commonly
used laboratory species, so we also assessed the potency of the
antagonists at histamine H1 and muscarinic receptors using
isolated ileal tissue segments to pharmacologically characterize
the compounds to be used and to extrapolate doses for the in
vivo anti-emetic part of the study. It was anticipated that the
detailed studies of GMA, temperature, respiratory function and
behavior coupled with c-fos would provide a comprehensive
understanding of mechanisms activated during provocative
motion. The use of selective H1 antihistamines and scopolamine
would provide benchmarks for future studies on motion sickness
using novel agents.
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METHODS
Animals
Adult male Suncus murinus (60–75 g, n = 178, 108 of
them used in vitro and 70 in vivo) were obtained from The
Chinese University of Hong Kong and housed in a temperature-
controlled room (24 ± 1◦C). Artificial lighting was provided
between 06:00 and 18:00 h. The relative humidity was maintained
at 50 ± 5%. Water and dry pelleted cat chow (Feline Diet
5003, PMI R© Feeds, St. Louis, USA) were given ad libitum unless
otherwise stated. All experiments were conducted under license
from the Government of the Hong Kong SAR and the Animal
Experimentation Ethics Committee, The Chinese University of
Hong Kong.
Organ Bath Studies
All animals were fasted overnight before being killed by cervical
dislocation. The whole intestine was then removed and placed
immediately in freshly prepared Krebs’ solution (118 mM NaCl,
4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4 7H2O, 2.5 mM
CaCl2 2H2O, 25 mM NaHCO3, and 10 mM glucose) and gassed
with 95 % O2 and 5% CO2 at room temperature. The ileum
was identified (Uchino et al., 2002) and a 1 cm segment was
removed and mounted longitudinally under 0.5 g tension in a 10
ml organ bath containing Krebs’ solution and gassed with 95%
O2 and 5% CO2 at 37
◦C. Only one isolated ileal section was
used from each animal (Chan et al., 2007). After an equilibration
period of 30 min, KCl (120 mM) was added to provide a
reference contractile response followed by a washout. Histamine
(100 nM–10 mM) was then added in a cumulative manner
using a 3–5 min dosing schedule. At the end of concentration-
response curve, KCl (120 mM) was added to check the viability
of ileal segments. Twelve animals were used in this part. The
mechanism of histamine to induce changes in smooth muscle
tension was also investigated briefly using tissues from 24 animals
(n = 6/treatment). Saline (0.9 w/v), tetrodotoxin (TTX, 1µM),
atropine (1µM), or hexamethonium (HEX, 500µM), was added
to the organ bath 20 min prior to the addition of histamine
(300µM; based on its EC50 values as determined from the
previous study). To estimate the effect of mepyramine and
cetirizine on histamine-induced contraction (doses cumulatively,
as before), tissues were equilibrated with mepyramine (0, 10,
30, and 100 nM) or cetirizine (0, 10, 30, and 100 nM) for 60
min, with regular washings every 20 min; Similarly, the effect
of scopolamine (0, 1, 3, and 10 nM) on acetylcholine-induced
contraction was also estimated. Seventy two animals were used
for these studies (n= 6/treatment). Isometric contractions of ileal
tissues were recorded using Grass transducers via a Mac Lab R©
system (ADInstruments Pty Ltd., New South Wales, Australia)
connected to a Power Macintosh G3 computer. Analytical
software (Chart, version 6.1, ADInstruments New South Wales,
Australia) was used to record data. The volume of drug solutions
added to the organ bath was less than 0.3% of the total volume.
Implantation of Radiotelemetry
Transmitters
Animals (n = 58) were fasted overnight and then injected with
buprenorphine (0.05 mg/kg, s.c. Temgesic R©), and anesthesia was
induced by ketamine (20 mg/kg, i.m.; Alfasan, Holland) and
xylazine (3mg/kg, i.m.; Alfasan, Holland), and maintained with
3 % isoflurane (Halocarbon Products Corporation, USA) in a
3:1 ratio of O2 to N2O using an anesthetic machine (Narkomed
2C, Drager, USA). They were then placed on a heating pad
(UCI#390 Analog moist heating pad, Rebirth Medical & Design,
Inc., Taiwan) and the level of anesthesia was assessed and
monitored throughout the surgery by the absence of the pedal
withdrawal reflex. Following a midline abdominal incision, the
distal stomach was exposed. Two biopotential wires of an ETA-
F20 transmitter (Data Sciences, Inc., USA) were inserted into
the serosal wall of antrum. The body of the transmitter was
placed subcutaneously on the dorsal aspect of the animal. The
abdominal cavity was closed using a continuous suture for
the muscle layer and a discontinuous suture for the skin; the
initial incision was sprayed with a permeable spray dressing
(Opsite R©, Smith and Nephew, UK). After surgery, all animals
were administered marbofloxacin (Marbocyl R©, 2 mg/kg, s.c.)
once per day for 3 days, and buprenorphine (0.05 mg/kg, s.c.)
was given again 12 h after the first dose. Animals were allowed 7
days to recover from the surgical procedures.
Experimental Protocols
Suncus murinus were initially pre-screened for motion
sensitivity. Briefly, animals were fasted overnight before
being put into clear Perspex whole body plethysmography
chamber (diameter, 19.1 cm; height, 14 cm; volume, 4,014.83
cm3; Data Sciences, Inc., USA) with airflow set at 2.5 L/min
provided by bias flow generator (Data Sciences, Inc., USA) for
30 min habituation followed by being presented with 10 g food.
One hour after feeding, animals were subjected to provocative
motion (1 Hz, 4 cm horizontal displacement, 10 min) triggered
by a shaker (Heidolph Promax, UK) followed by a further 1 h
recording. A range of animal behaviors (see below), including
emesis, body temperature, gastric myoelectric activity (GMA),
and respiratory activity were recorded.
Seven days later, animals exhibiting emesis in pre-screening
were used to assess the anti-emetic potential of the antihistamines
and scopolamine. These animals were randomized into different
treatment groups (group of saline, mepyramine, cetirizine, and
scopolamine) using a Latin square design. Drugs or vehicle
(saline 2 ml/kg, i.p.) were administrated 1 h before provocative
motion (1 Hz, 4 cm horizontal displacement, 10 min) followed
by a further 1 h recording; telemetric, respiratory and behavioral
data were acquired through the whole recording period. Animals
were then deeply anesthetized with pentobarbitone (80 mg/kg,
i.p.) (Dorminal R©, Alfasan, Woerden, Holland) and intracardially
perfused with pre-cooled (4◦C) saline (40 ml) followed by 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS, 80
ml). Brains were removed and post-fixed in 4% PFA overnight at
4◦C. After fixation, brains were transferred into 15% sucrose/4%
PFA for dehydration overnight or until they sank, then to 30%
sucrose/4% PFA until they sank again before being placed in
aluminum foil containers filled with O.C.T. compound (Tissue-
Tek, Sakura, USA). Samples were then stored at −80◦C until
sectioning for c-fos immunohistochemistry. Four sets of 12
animals, 3 in each set, were used as negative controls of vehicle,
mepyramine, cetirizine, and scopolamine, separately, which were
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subjected to the same protocol as the corresponding group, but
without motion.
c-Fos Immunohistochemistry
The methodology for c-fos immunohistochemistry followed that
previously used in studies of pathways implicated in emesis
in Suncus murinus (Chan et al., 2013, 2014). In brief, frozen
tissues were sectioned at 40 µm in the coronal plane using
a freezing microtome and incubated at room temperature for
1 h in 0.03% H2O2. The free-floating sections were blocked
with 1.5% normal goat serum containing 0.3% Triton X-
100 in PBS (Vectastain Elite ABC kit, Vector Laboratories,
Burlingame, USA) for 1 h. After washing three times with PBS,
sections were then incubated with rabbit anti-c-fos antibody
(1: 10,000; Oncogene Research Products, Cambridge, USA)
for 48 h at 4◦C. The sections were subsequently washed
and incubated with secondary goat-anti-rabbit antibody (1:200;
Vector Laboratories) for 1 h, followed by Vectastain avidin–
biotin complex reagent for 1 h (1:100; Vectastain Elite ABC kit,
Vector Laboratories, Burlingame, USA). c-Fos expression was
visualized using a commercially available peroxidase substrate
(Vector R© VIP kit, Vector Laboratories, Burlingame, USA). The
number of c-fos immunoreactive cells was counted manually
using a Zeiss Axioskop 2 plus microscope (Carl Zeiss Inc.
Thornwood, USA) equipped with a Zeiss Axiocam 2 camera.
To quantify expression in brainstem and hypothalamic nuclei,
three representative sections were selected in accordance with
the stereotaxic atlas constructed from our previous studies
(Chan et al., 2013, 2014). Specifically, the anterior-posterior
coordinates (measured from lambda) of the sections in which c-
Fos were counted:+5.32,+5.44, and+5.66 for the ventral medial
nucleus of hypothalamus (VMH), dorsal medial nucleus of
hypothalamus (DMH), peduncular part of lateral hypothalamus
(PLH), and arcuate nucleus (Arc); +5.92, +6.04, and +6.28 for
paraventricular nucleus of hypothalamus (PVH); +0.50, +0.62,
and 0.74 for medial vestibular nucleus (MVe);−0.26,−0.14, and
−0.02 for the area postrema (AP) and nucleus tractus solitarius
(NTS). The individual who performed all the counts was unaware
of the treatment that the animals had received.
Data Acquisition and Analysis
Behavior
Emesis was characterized as rhythmic abdominal contractions
that were either associated with oral expulsion of solid or liquid
material from the gastro-intestinal tract (i.e., vomiting), or not
associated with passage of material (i.e., retching). An episode
of retching and/or vomiting was considered separate when the
animal changed its location inside the plethysmography chamber,
or when the interval between retches and/or vomits exceeded
2 s (Rudd et al., 1999). Emetic events changed the pressure
waveforms in the chamber and this was analyzed using a “burst
analysis” technique (see below). Behaviors recorded were: sniffing
(animal draw in a scent or air through nasal cavity inside
the chamber; face washing (animal scratching its face with its
forelimbs); chin on the floor (animal scratching its floor with its
chin); scratching (animal use its hind limbs scratch its body);
licking (tongue protrusion and movement—occurring during
lying flat, resting, and periods where the animals actively moved
around the chamber); lying flat (animal lying down with its
stomach fully on floor, with the appearance of sedation); resting
(animal conscious, but not moving). All behaviors were recorded
as episodes, except resting and lying flat, which were recorded
in min. JWatcher 1.0 software (Macquarie University, Sydney,
Australia) was used to record behaviors.
Radiotelemetry
GMA data were initially analyzed using Spike2 R© (Version 8.1,
Cambridge Electronic Design, UK) with methods previously
developed by our laboratory (Percie du Sert et al., 2010). In brief,
the gastric slow waves were recorded with a sampling frequency
of 1,000 Hz, which were then subsequently filtered in several
steps to a 0.03–0.5 Hz (2–30 cycles min−1) window, and down-
sampled to 10.24 Hz to remove cardiac and respiratory signals,
and low-frequency artifacts such as movement. Fast Fourier
transforms (FFTs, Hann window, 2048) were computed on
successive 10-min sections of data, and the following parameters
were used to characterize the GMA: dominant frequency (DF)
is defined as the frequency bin with the highest power in the
2–24 cpm range; dominant power (DP) is the highest power in
the 2–24 cpm range; the repartition of power in bradygastric 2
to DF−2 cpm, normal DF−2 to DF+2 cpm and tachygastric
(DF+2–24 cpm) ranges (i.e., bradygastria, normogastria, and
tachygastria). All data collected by radiotelemetry including core
body temperature were calculated by taking average of the data
per 10 min.
We also used advanced analytical techniques to examine
the structure of the slow waves. Thus, multifractal detrended
fluctuation analysis (MFDFA) was used to obtain singularity
spectra (α) (Kantelhardt et al., 2002); the multifractal spectrum
identifies the deviation in fractal structure with time, compared
with large and small fluctuations (Ihlen, 2012). Generally, the
multifractal spectrum [plot f(α) vs. α] of signals with multifractal
organization have a concave downward curvature. The width
(1α = α max − αmin) of singularity spectra has been used to
characterize the spectra, which is a measure of complexity of the
multifractal process. We used Spike2 R© (Version 8.1, Cambridge
Electronic Design, UK) with custom scripts to perform the
MFDFA.
Respiration
Whole body plethysmography has been previously used in
Suncus murinus to semi-automate the recording of emetic
events (Tashiro et al., 2007), but the methodology described
here enabled the first detailed quantification of respiratory
parameters using compensated whole body plethysmography
(500-05RevA, Data Sciences, Inc., USA). The system consisted
of two transparent chambers, each equipped with a Validyne
pressure transducer (600–900 mmHg), a temperature sensor (0–
100◦C), and a humidity sensor (0–100 %). All channel signals
from the two chambers were collected using ACQ7700 Carrier
and UniversalXE Signal Conditioner collected to a Micro 1401
data acquisition unit (Cambridge Electronic Design, UK). Signals
were thereafter acquired and analyzed using Spike2 R© (Version
8.1, Cambridge Electronic Design, UK) running on a PC desktop
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computer. It should be noted that animal body temperature is a
prerequisite for calculating the respiratory tidal volume, and real
time body temperature data from the telemetry transmitters was
used in the calculation using oﬄine processing inMicrosoft Excel
2010 (v14.0, USA).
For characterizing the respiratory pattern, several parameters
were used: respiratory rate, tidal volume, and inspiration time
and flow, which was inclusive of regular respiratory activity
and/or sniffing (See Figure 1A). Respiratory rate, which is
the mean of the inter-breath interval, was computed from
troughs in the respiratory signals. Respiratory data, excepting
respiration rate, could not be collected during motion due
to disruption of recordings caused by the shaking of the
recording equipment. Therefore, only mean frequency was
available to use for evaluation of respiratory function during
motion. Moreover, respiratory signals were also discarded
from the analysis during emetic episodes. All data were
calculated by taking the average of the data per 2 min,
before eventually averaging into 10 min segments for statistical
analysis.
Analysis of Emetic Data Using Burst Analysis
plethysmographic chamber pressure recordings: episodes of
retching and/or vomiting interrupted and altered respiratory
recordings (See Figure 1B). Usually, the inspiration flow for
normal respiration is 0.2–1 ml/s. During a retch or vomit,
the flow is approximately 3–5 ml/s, as evidenced by a cluster
of sharp peaks (each peak representing a single retch or
vomit) (Tashiro et al., 2007); these peaks were not necessarily
related to lung volume, but more likely to represent a
change of animal shape/volume during the physical process
of retching or vomiting. Six parameters were defined to
enable automated burst analysis using Spike2: events per
episode, mean inter-event duration, mean retch/vomit frequency,
episode duration, interval between episodes (the duration
from the end of last episode to the start of the next
episode) and cycle between episodes (the duration from the
onset of last episode to the start of the next episode) (See
Figure 1B).
Statistical Analyses
All statistical analyses were performed using Prism version
6.0 (GraphPad, California, USA). Difference between ileal
tension, and all data obtained during pre-screening study
including animal behavior and emesis, and all parameters of
GMA and respiratory pattern were assessed using one-way
ANOVA followed by a Bonferroni’s multiple comparison
tests. The method to calculate pA2 and pKb values was
described previously (Schild, 1947; Gaddum et al., 1955). The
differences between animal behaviors, and all parameters of
GMA, and respiration patterns among vehicle, mepyramine,
cetirizine, and scopolamine groups were assessed using
repeated two-way ANOVA (factors: time and treatment),
followed by Bonferroni test. Pearson’s correlation was
used to assess correlations among episodes, DF, DP, body
temperature, respiration rate, body weight, bradygastria,
normogastria, tachygastria, and tidal volume values, which were
obtained in the pre-screening study. During our analysis,
baseline refers to a 10 min period immediately before
provocation motion; recovery indicates 10 min immediately
after provocation motion. All data are expressed as the
mean ± s.e.m. Differences were considered significant when
p< 0.05.
Drug Formulation
Histamine dihydrochloride, tetrodotoxin (TTX), atropine
methylnitrate, hexamethonium bromide (HEX), and
scopolamine hydrochloride were from Sigma-Aldrich, St.
Louis, USA. Mepyramine maleate, cetirizine dihydrochloride
were from Tocris, Bristol, UK. All drugs were dissolved in saline
(0.9%, w/v).
RESULTS
The Effect of Mepyramine and Cetirizine on
Histamine-Induced Contractions of the
Isolated Ileum
Histamine caused a small transient relaxation between 100
nM and 1µM. At higher concentrations of 3µM–10mM,
the response was biphasic, manifested as an initial transient
relaxation followed by a sustained contraction. The contractile
action had a pEC50 of 4.1 ± 0.2 with an Emax of 82.4 ±
8.3% (120mM KCl response); the transient relaxation effect
ranged from −2.4 ± 1.0 % to −11.5 ± 2.9 % (120mM KCl
response) (Figure 2A). The contractile action was significantly
reduced by 52% by tetrodotoxin (1µM) (p < 0.01), but not
by atropine (1µM) or hexamethonium (500µM) (Figure 2B).
Mepyramine (10–100 nM) and cetirizine (10–100 nM) caused
a progressive rightward shift of the concentration-response
curves to histamine, with depression of maxima (Figures 2C,E).
Acetylcholine induced a contraction of the ileum, with a pEC50
of 6.3± 0.2 and an Emax of 87.5± 8.9 % (120mMKCl response).
Scopolamine (1–10 nM) caused a progressive rightward shift
of the concentration-response curves to acetylcholine, without
depressing the maxima (Figure 2G). Double reciprocal analysis
of mepyramine and cetirizine, and Schild analysis of scopolamine
plots yielded pKb values of 7.5 and 8.4, and pA2 value of 9.5,
respectively (Figures 2D,F,H). Mepyramine and cetirizine failed
to affect the minor relaxant effect of histamine during these
experiments.
Behavior Observations
Suncus murinus were initially pre-screened for motion
sensitivity, of which 87.9% had emesis: in the responding animals
the latency was 4.7 ± 0.4 min and there were 8.4 ± 0.6 episodes
occurring with 4.3 ± 0.5 vomits and 35.3 ± 2.7 retches (n = 51).
Motion induced a reduction in the number of episodes of sniffing
(Table 1, p < 0.001) and increased the number of episodes of
scratching (Table 1, p< 0.001), without affecting other behaviors
in the 1 h period following motion, in comparison with the
preceding 1 h basal behavior before motion. Animals became
motionless soon after the onset of motion until the end of
motion.
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FIGURE 1 | Illustration of the respiratory pattern of Suncus murinus and analysis of emetic data using burst analysis. (A) Illustration showing elements of the
respiratory cycle (inspiration downwards). Mean respiratory rate, tidal volume, inspiration time and inspiration flow were used to characterize the respiratory pattern;
(B) Illustration of the raw recording and analysis of emetic data using burst analysis. “Events” are large-amplitude single oscillatory cycles that coincided with visually
observed contraction of abdominal muscles. Events per episode, mean inter-event duration, mean retch/vomit frequency, episode duration, interval between episodes
(the duration from the end of last episode to the start of the next episode) and cycles between episodes (the duration from the onset of last episode to the start of the
next episode) were defined to enable automated analysis of emetic episode data.
Effect of Provocative Motion on GMA,
Body Temperature, and Respiratory
Pattern of Suncus murinus
During pre-screening, the baseline DF was 14.7 ± 0.2 cycle/min
(cpm) with a DP of 2.6 ± 0.4 ∗ 10−4 mv2. 26.3 ± 1.9% of
power was in the bradygastric range, 43.6 ± 2.6% of power was
in the normogastric range, and 18.2 ± 1.2% of power was in
the tachygastric range (n = 58). In the responding animals (n
= 51), motion caused a 6.2% increase in the % power of the
bradygastric range (Table 2, p < 0.01), whilst causing a 12.1%
decrease the % power of the normogastric range (Table 2, p
< 0.001). A slight fall in body temperature was also observed
during motion (−0.3 ± 0.04◦C) and recovery (−0.6 ± 0.1◦C)
(Table 2, p < 0.001). Animals exhibited a basal respiratory rate
of 243 ± 24 breaths per minute (bpm), a tidal volume of
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FIGURE 2 | Effect of mepyramine and cetirizine on histamine-induced, and scopolamine on acetylcholine-induced contractions of Suncus murinus isolated ileal
sections. (A) Concentration-response curve of histamine against ileal sections; (B) Effect of TTX, HEX, and atropine on histamine-induced contraction of isolated
ileum; (C,E) Effect of mepyramine and cetirizine on histamine-induced contraction of isolated ileum; (D,F) Double reciprocal plot for histamine in the presence of 30
nM mepyramine and cetirizine, respectively; (G) Effect of scopolamine on acetylcholine-induced contraction of isolated ileum; (H) Schild analysis of scopolamine on
acetylcholine-induced contractions. Data represents mean ± s.e.m. of 6–12 determinations. Significant differences compared to the control group are indicated as
**p < 0.01 (One-way ANOVA followed by Bonferroni test).
0.47 ± 0.02ml, an inspiration time of 0.12 ± 0.01 s, and an
inspiration flow of 0.58 ± 0.03ml/s. There was a ∼132 bpm
increase (54% increase) of respiration rate (Table 2, p < 0.001)
during motion. Compared to baseline, a ∼129 bpm increase
of respiration rate and a ∼0.13ml reduction in tidal volume
(Table 2, p < 0.001), concomitant with a 0.04 s reduction in
inspiration time (Table 2, p < 0.001) and a ∼0.09ml/s increase
of inspiratory flow (Table 2, p < 0.001) were observed during
recovery period.
Effect of Mepyramine, Cetirizine, and
Scopolamine on Animal Behavior and
Motion-Induced Emesis
Consistent with the pre-screening study, a range of animal
behaviors were quantified following drug/vehicle administration.
Sedation, represented by lying flat, was only observed following
mepyramine (Table 3, p < 0.001), and the animals also spent
less time resting (Table 3, p < 0.001). The mepyramine-treated
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TABLE 1 | Effect of provocative motion on spontaneous behaviors in Suncus
murinus.
Spontaneous behaviors
before motion (60 min)
Spontaneous behaviors
after motion (60 min)
Face washing 2.9 ± 0.5 2.0 ± 0.5
Chin on the floor 3.9 ± 1.1 3.7 ± 1.0
Scratching 17.7 ± 3.7 30.4 ± 4.8***
Sniffing 25.4 ± 3.1 12.0 ± 1.7***
Licking 3.2 ± 1.0 4.5 ± 1.7
Resting (min) 39.5 ± 3.0 37.8 ± 2.6
Resting is calculated in mins, other behaviors are calculated in episodes. Data represents
the mean ± s.e.m. of 24 animals. Significant differences compared to baseline are shown
as ***p < 0.001 (paired t-test).
animals also had fewer episodes of scratching compared to the
vehicle group (Table 3, p < 0.001). Cetirizine and scopolamine
did not affect the behavior of the animals (Table 3, p> 0.05).
Vehicle-treated animals exhibited 9.8 ± 1.4 episodes during
provocative motion, which consisted of 5.8 ± 1.8 vomits and
61.7 ± 7.4 retches (Figures 3A–C, n = 6). Both mepyramine
and scopolamine, but not cetirizine, significantly antagonized
motion-induced emesis in terms of number of episodes, vomits,
and retches (Figures 3A–C). When compared with the number
of episodes of vomiting and/or retching during pre-screening,
mepyramine and scopolamine caused a significant reduction by
86 ± 7.0% (p < 0.01) and 59 ± 8.5% (p < 0.05) as shown
in Figure 3D. None of the treatments affected the latency to
the first episode of retching and/or vomiting (vehicle, 3.7 min;
mepyramine, 6.1 min; cetirizine, 4.7 min; and scopolamine, 5.6
min; median values).
Burst Analysis of Emetic Data
In our experiments, a “retch/vomit” refers to a single high-
amplitude wave of pressure change during an emetic episode
(Figure 1B). Vehicle, cetirizine, and scopolamine-treated
animals had 6.5 ± 0.2, 6.4 ± 0.3, and 7.2 ± 1.4 retches+vomits
per emetic episode, respectively (Figure 4A, n = 6, p > 0.05).
In comparison, the animals treated with mepyramine had
10.1 ± 0.4 retches+vomits per emetic episode, which was
significantly higher than the other three groups (Figure 4A,
p < 0.01). Similarly, the mean retches+vomits frequency,
and emetic episode duration, all increased significantly (p
< 0.01) in the mepyramine-treated group (Figures 4B–D).
There was no difference between data for any of the
treatment groups with respect to the intervals between
episodes, or the cycles between episodes (Figures 4E,F, p >
0.05).
Effect of Mepyramine, Cetirizine, and
Scopolamine on Gastric Myoelectric
Activity and Body Temperature
Baseline data for animals prior to randomization was: DF =
15.6 ± 0.2 cpm; DP = 5.7 ± 0.2 ∗ 10−4 mv2; and 28.3 ±
1.6% of power was in the bradygastric range; 35.1 ± 2.7% of
power was in the normogastric range; and 22.7 ± 1.7% of power
was in the tachygastric range (n = 24). Only pre-treatment
TABLE 2 | Effect of provocative motion on gastric myoelectric activity, body
temperature, and respiratory pattern.
Baseline Motion Recovery
DF (cpm) 14.67 ± 0.20 14.42 ± 0.28 15.06 ± 0.27
DP (*10−4 mv2 ) 2.59 ± 0.40 2.37 ± 0.33 2.96 ± 0.43
Bradygastria (%) 26.26 ± 1.88 32.45 ± 2.28** 28.28 ± 1.98
Normogastria (%) 43.55 ± 2.59 31.44 ± 2.17*** 36.76 ± 2.67
Tachygastria (%) 18.21 ± 1.22 20.07 ± 1.32 21.63 ± 2.06
Body Temperature (◦C) 34.70 ± 0.13 34.41 ± 0.13*** 34.16 ± 0.16***
Respiration Rate (bpm) 243.30 ± 23.64 375.30 ± 16.10*** 372.20 ± 20.52***
Tidal Volume (ml) 0.47 ± 0.02 – 0.34 ± 0.01***
Inspiration Time (s) 0.12 ± 0.01 – 0.08 ± 001***
Inspiration Flow (ml/s) 0.58 ± 0.03 – 0.67 ± 0.03**
Data represents the mean± s.e.m. of 44–52 animals. Significant differences compared to
baseline are shown as **p < 0.01, ***p < 0.01 (One-way ANOVA followed by Bonferroni
tests). Baseline refers to a 10 min period immediately before provocation motion; recovery
indicates 10 min immediately after provocation motion.
of animals with mepyramine affected the DF, with an 18.4%
reduction being recorded (Figure 5A, p < 0.01). There was no
significant difference among all groups for DP (Figure 5B, p >
0.05). The % power in the bradygastric range of the mepyramine-
treated animals was also significantly higher than in the vehicle-
treated animals (Figure 5C, p < 0.05). Consistent with the
initial pre-screening study, the % power in the bradygastric
range in the vehicle group increased (∼50%) significantly during
motion when compared with baseline (Figure 5C, p < 0.05).
Mepyramine-, cetirizine-, and scopolamine-treated animals had
a significant lower % of power in the normogastric range in
comparison with vehicle group during baseline (Figure 6D, p
< 0.05). A reduction in the % power of normogastria (∼46%)
during motion was only observed in vehicle group and is
consistent with data obtained during pre-screening (Figure 6D,
p < 0.01). The % power of tachygastria was not significantly
different among the four groups during motion (Figure 6E,
p > 0.05). With respect to subcutaneous temperature, there
was no significant difference among vehicle, cetirizine- and
scopolamine- treated groups during the 60 min pre-treatment
time. Conversely, mepyramine-caused a substantial fall of
∼2.5◦C (Figure 6F, p < 0.01). A drop of temperature elicited
by provocative motion was subsequently observed in vehicle-,
cetirizine-, and scopolamine-treated animals, with maximum
drops of 0.92 ± 0.2◦C, 0.26 ± 0.2◦C, and 0.74 ± 0.2◦C,
respectively (Figure 6F). There was a continuous but slight drop
in body temperature during 1 h further recording after motion
in scopolamine treated animals, while animals in both vehicle
and cetirizine groups remained stable. Body temperature in
mepyramine-treated animals gradually returned to normal by
the end of the 1 h period. There was no significant difference
among the four groups at the endpoint of recording (data not
shown).
Effect of Mepyramine, Cetirizine, and
Scopolamine on Respiration Pattern
The respiratory pattern was essentially the same as observed in
the initial screening experiments (above). Basal data prior to
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TABLE 3 | Effect of mepyramine (50 mg/kg), cetirizine (10 mg/kg), and scopolamine (10 mg/kg) on spontaneous behaviors in Suncus murinus.
Basal spontaneous behavior before motion (60 min) Basal spontaneous behavior after motion (60 min)
Vehicle Mepyramine Cetirizine Scopolamine Vehicle Mepyramine Cetirizine Scopolamine
Face washing 5.8 ± 3.4 0.2 ± 0.4 2.8 ± 1.3 1.2 ± 0.6 1.7 ± 2.7 0.2 ± 0.4 1.3 ± 1.8 1.5 ± 0.8
Chin on the floor 13.5 ± 12.1 17.8 ± 15.8 5.0 ± 5.4 9.0 ± 4.4 1.3 ± 1.5 5.2 ± 6.2 1.2 ± 2.9 0.7 ± 0.3
Scratching 22.1 ± 9.0 1.3 ± 2.1*** 9.3 ± 9.1 16.5 ± 5.5 15.7 ± 12.9 25.7 ± 17.4 8.8 ± 8.2 17.0 ± 8.0
Sniffing 33.3 ± 11.5 22.7 ± 7.8 28.5 ± 15.4 26.8 ± 9.0 9.3 ± 7.4 9.0 ± 8.9 7.0 ± 6.1 10.0 ± 4.4
Licking 4.5 ± 6.4 0.3 ± 0.5 1.7 ± 3.6 5.7 ± 1.9 2.8 ± 1.8 3.3 ± 7.2 2.3 ± 3.9 3.0 ± 1.5
Lying flat (min) 0 26.7 ± 12.7*** 0 0 0 2.9 ± 6.7 0 0
Resting (min) 35.2 ± 9.1 7.7 ± 8.1*** 42.6 ± 3.6 37.3 ± 4.5 50.2 ± 4.6 41.2 ± 12.6 39.2 ± 1.2 45.0 ± 3.3
Resting and lying flat are calculated in mins, other behaviors are calculated in episodes. Data represents the mean ± s.e.m. of 6 animals. Significant differences compared to vehicle
group are shown as ***p < 0.001 (One-way ANOVA followed by Bonferroni tests).
FIGURE 3 | Effect of mepyramine (50 mg/kg), cetirizine (10 mg/kg), and scopolamine (10 mg/kg) on motion-induced emesis in Suncus murinus. (A) Number of
episodes of emesis; (B) Number of vomits; (C) Number of retches; (D) % change from pre-screening episodes. Drug or vehicle was administered intraperitoneally as a
60 min pretreatment. Results represent the mean ± s.e.m. of 6 animals. Significant differences compared to vehicle group are shown as *p < 0.05, **p < 0.01
(One-way ANOVA followed by Bonferroni tests). Veh, vehicle; Mep, mepyramine; Cet, cetirizine; Sco, scopolamine.
randomization was: respiratory rate of 349.9 ± 19.8 bpm; tidal
volume was 0.44 ± 0.02 ml; inspiration time was 0.09 ± 0.004
s; and inspiration flow was 0.72 ± 0.03 ml/s (n = 24). There
was no significant difference in respiration rate among all groups
during the baseline period (Figure 6A, p > 0.05). However,
the respiration rate increased significantly during motion in
vehicle, cetirizine and scopolamine, but not in mepyramine
treated animals (Figure 6A, p > 0.05); the increase was ∼42.7%
above baseline values (Figure 6A, p< 0.01). During the recovery
period, there was also a significant reduction in tidal volume
in all groups compared with baseline (Figure 6B, p < 0.01),
but the reduction appeared less for mepyramine group, which
remained significantly higher than vehicle group (Figure 6B, p
< 0.05). In terms of inspiration time, it dramatically decreased
during the recovery period in both the vehicle and cetirizine
groups compared with baseline (Figure 6C, p < 0.01), but not in
the mepyramine and scopolamine groups (Figure 6C, p > 0.05).
Inspiration time in mepyramine group was significantly higher
than for the other three groups during recovery (Figure 6C,
p < 0.05). There was no significant difference in inspiration
flow among all groups during the recovery period (Figure 6D,
p> 0.05).
Correlations of Physiological Parameters
and MFDFA Analysis of GMA
The physiological parameters obtained from the pre-screening
study were used to perform correlative analyses during
the baseline, motion, and recovery periods, respectively.
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FIGURE 4 | Analysis of emetic data using burst analysis. (A) Events per episode/burst; (B) Mean inter-event duration; (C) Mean retch/vomit frequency; (D) Episodes
duration; (E) Interval between episodes; (F) Cycle between episodes. Results represent the mean ± s.e.m. of all animals which vomited (n = 3–6). Significant
differences compared to vehicle group are shown as **p < 0.01 (One-way ANOVA followed by Bonferroni tests). Veh, vehicle (saline, 2 ml/kg); Mep, mepyramine
(50mg/kg); Cet, cetirizine (10mg/kg); Sco, scopolamine (10mg/kg).
Episode data correlated positively with respiration rate
during motion and recovery with p-values of 0.017 and
0.006, respectively (Supplementary Figures 1A,B). Moreover,
several positive correlations were also observed between
DF and body temperature during baseline, motion and
recovery with p < 0.0001, 0.007, and 0.0028, respectively
(Supplementary Figures 1C–E). A retrospective analysis of data
between animals that had vomited and not vomited showed
a significant difference in body temperature during baseline,
motion and recovery (Supplementary Figures 2A–C, p< 0.05; p
< 0.05; p < 0.01, respectively). However, there was no difference
in 1 temperature between animals that had vomited and those
resistant to motion (Supplementary Figure 2D, p > 0.05). In
the animals that had emesis, no significant correlation was
observed between the number of episodes of emesis and basal
body temperature or1 temperature (data not shown).
MFDFA analysis of GMA did not reveal significant differences
for the width of singularity strength 1α of between baseline,
motion and recovery periods during the pre-screening study
(1.24 ± 0.03 vs. 1.17 ± 0.03 vs. 1.23 ± 0.03, respectively, p
> 0.05) (Supplementary Figure 3A). A representative multi-
fractal spectrum graph is shown in Supplementary Figure 3B.
Raw traces of GMA from baseline, motion and recovery periods
are also shown in Supplementary Figure 3C. No significant
difference in 1α was observed among all the groups during
drug/vehicle treatment (Supplementary Table 1).
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FIGURE 5 | Effect of mepyramine (50mg/kg), cetirizine (10mg/kg), and scopolamine (10mg/kg) on gastric myoelectric activity and core body temperature.
(A) Dominant frequency (DF); (B) Dominant power (DP); (C) Bradygastria %; (D) Normogastria %; (E) Tachygastria %; (F) Body temperature. Data represents the mean
± s.e.m. of 6 animals. For inter-group comparison, significant differences compared to vehicle group are shown as *p < 0.05, **p < 0.01 (repeated measures two-way
ANOVA followed by Bonferroni tests), #p < 0.05, ##p < 0.01 (repeated measures two-way ANOVA followed by Bonferroni tests) was applied when referring to
intra-group comparison. Baseline refers to a 10 min period immediately before provocation motion; recovery indicates 10 min immediately after provocation motion.
Effect of Mepyramine, Cetirizine, and
Scopolamine on Motion-Induced c-Fos
Expression in Brain
Representative photomicrographs of c-fos staining in the
brainstem are shown in Figure 7. In the vehicle group, 10 min
of provocative motion itself did not induce c-fos expression in
AP, NTS, MVe, VMH, DMH, PLH, PVH, and Arc compared
with the negative control of vehicle group (same protocol, but
without motion) (Figure 8, p > 0.05). However, mepyramine,
but not cetirizine or scopolamine, caused a significant increase
in c-fos expression in AP, NTS MVe, VMH, DMH, PLH, PVH,
and Arc compared with the vehicle group in animals exposed to
motion (Figure 8, p< 0.001). Mepyramine alone without motion
(shammotion conditions) also induced significant increases in c-
fos expression in the brain areas that we focussed on (Figure 8, p
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FIGURE 6 | Effect of mepyramine (50 mg/kg), cetirizine (10 mg/kg), and scopolamine (10 mg/kg) on respiratory pattern. (A) Respiratory rate; (B) Tidal volume;
(C) Inspiration time; (D) Inspiration flow. Data represents the mean ± s.e.m. of 6 animals. For inter-group comparison, significant differences compared to vehicle
group are shown as *p < 0.05 (repeated measures two-way ANOVA followed by Bonferroni tests), significant differences compared to baseline are shown as #p <
0.05, ##p < 0.01 (repeated measures two-way ANOVA followed by Bonferroni tests) when referring to intra-group comparison. Baseline refers to a 10 min period
immediately before provocation motion; recovery indicates 10 min immediately after provocation motion.
< 0.001). In other brain areas such as ventral and dorsal part of
medullary reticular nucleus, the caudal part of spinal trigeminal
nucleus, and the hypoglossal nucleus, there were no detectable
increase in c-fos, indicating that the effects of mepyramine
were not non-specific in nature. Cetirizine and scopolamine
alone, without motion, did not cause c-fos expression in the
brain.
DISCUSSION
The present investigation is the first to use radiotelemetry in
conjunction with whole body plethysmography to investigate
mechanisms of emesis and respiratory function in conscious
Suncus murinus. This enabled a unique insight into the
mechanisms of motion-induced emesis and changes in
behavior, gastric myoelectric activity (GMA), and respiration
during treatment with brain penetrating (mepyramine)
and non-brain penetrating (cetirizine) antihistamines and
the muscarinic receptor antagonist, scopolamine. Below
we discuss the use of this novel combined approach
to recording emesis, reassess the role of histamine and
muscarinic receptors in motion sickness, and consider the
insights into central emetic pathways provided by the c-fos
analysis.
Baseline Respiratory, Temperature, and
GMA Values and the Response to Motion
Our experimental design permitted a collection of a vast amount
of basal data as we prepared to screen for motion sensitivity.
Thus, we report for the first time the respiratory parameters
of conscious Suncus murinus (mean weight ∼65 g). In our
studies, we also corrected volume measurements for real-time
body temperature, which improves accuracy of calculations.
Suncus murinus had a respiratory frequency of ∼243 bpm and
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FIGURE 7 | Representative photomicrographs illustrating c-fos expression (violet nuclear label) in the caudal brainstem after administration of saline (2 ml/kg),
mepyramine (50mg/kg), cetirizine (10mg/kg), and scopolamine (10mg/kg). Veh/MS, vehicle and motion stimulus; Mep/MS, mepyramine and motion stimulus;
Cet/MS, cetirizine and motion stimulus; Sco/MS, scopolamine and motion stimulus; Veh, saline without provocative motion; Mep, mepyramine without provocative
motion; Cet, cetirizine without provocative motion; Sco, scopolamine without provocative motion. Arrows show some of the activated c-fos positive cells. AP, area
postrema; NTS, nucleus tractus solitarius. Scale bar: 100 µm.
a tidal volume of ∼0.47ml. These values are at least twice
as high as reported for mice (∼20 g) (Mitzner et al., 2001;
Mozzini Monteiro et al., 2016). Body temperature (measured
subcutaneously) was ∼35◦C and GMA was typified by a DF
of 15 cpm, with 44% of the percentage power being in the
normogastric range, which is consistent with our previous studies
(Percie du Sert et al., 2010). Behaviorally, the animals were
not particularly active when placed in the respiratory recording
chamber, spending about 65% of the time resting, with scratching
and sniffing predominating as behaviors.
Predictably, motion-induced emesis was easily visible, but we
could not confidently score other behaviors when the chamber
was moving. However, from the pressure waveforms, we could
reliably identify emetic events, with burst analysis showing
approximately 6.5 retches/vomits per episode, which is similar
to that recorded in other studies of either conscious (6.5 ±
0.2 retches/episode) or anesthetized (7.1 ± 0.7 retches/episode)
Suncus murinus (Andrews et al., 1996; Huang et al., 2011). We
also identified that respiratory rate increased by ∼59%, with
a concurrent 28% reduction in tidal volume (inspiratory time
also reduced) during motion; increases in respiratory rate of the
order of about 4–12% are also seen in humans experiencing
nausea induced by a simulated roller coaster ride (Gavgani
et al., 2016) and in dogs motion-induced emesis may also be
accompanied by panting (Crampton, 1990). A recently published
clinical study demonstrated that motion also induced an increase
of respiratory rate, oxygen consumption and carbon dioxide
production, and these effects were more prominent in highly-
susceptible participants (Chen et al., 2016). During the recovery
period, the respiratory rate remained elevated and the tidal
volume remained lower. There was also an increase in scratching
activity and a decrease in sniffing. There was a positive correlation
between respiratory rate and the number of emetic episodes
during motion and the recovery period, but it is not known if
this relates more to the stress of the tests, since high respiratory
frequency and reduced sniffing is a characteristic of anxiety
in rodents (Carnevali et al., 2013). Nevertheless, any potential
contribution of an increase in respiratory rate with links to
forebrain functioning (e.g., anxiety or “nausea”) needs to bemade
cautiously since such changes also occur prior to emetic episodes
induced by electrical or chemical stimulation of brain pathways
and can be seen in anesthetized and decerebrate animals (Bradley
et al., 1987; Koga and Fukuda, 1990; Howard and Sears, 1991).
As regards GMA, motion induced a reduction in normogastria
(Percie du Sert et al., 2010) and there was also a slight fall in
body temperature (Ngampramuan et al., 2014; Tu et al., 2017);
the latter effect has been documented consistently across several
species and has been suggested to be associated with nausea
(Nalivaiko et al., 2014). Whilst motion clearly affected the % of
power partitioning of GMA, MFDFA revealed that the actual
structure of the slow waves themselves did not appear to be
disrupted.
The Role Histamine and Acetylcholine
Receptors in Motion-Induced Emesis
Suncus murinus is an established model for investigation of
motion sickness (Ueno et al., 1987, 1988). Previous studies
using this species showed that older generation brain penetrant
antihistamines, with additional muscarinic receptor blocking
activity (e.g., promethazine, diphenhydramine; 20–50 mg/kg),
have some activity to reduce (∼22% reduction) motion-induced
emesis, whereas the H1 selective antihistamine, mepyramine
(pyrilamine; 20 mg/kg), is less effective (∼11%) (Ueno et al.,
1988). Comparatively, a more marked effect (50∼90% reduction
in episodes) is observed following treatment with histamine
depleting agents (Kaji et al., 1991), indicating a more prominent
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FIGURE 8 | Effect of mepyramine (50 mg/kg), cetirizine (10 mg/kg), and scopolamine (10 mg/kg) on motion-induced c-fos expression in the brain of Suncus murinus.
Data represents the mean ± s.e.m. of 6 animals. (A) Area postrema; (B) Nucleus tractus solitarius; (C) Medial vestibular nucleus; (D) Ventromedial hypothalamic
nucleus; (E) Dorsomedial hypothalamic nucleus; (F) Bednucleus part of lateral hypothalamus; (G) Paraventricular hypothalamic nucleus; (H) Arcuate hypothalamic
nucleus. NC, vehicle control (saline without provocative motion); MC, mepyramine control (mepyramine without provocative motion); CC, cetirizine control (cetirizine
without provocative motion); SC, scopolamine control (scopolamine without provocative motion). Significant differences compared to vehicle group or the negative
control group are shown as **p < 0.01, ***p < 0.001 (One-way ANOVA followed by Bonferroni tests).
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role for histamine (possibly mediated via other histamine
receptors) than indicated by the antagonist studies. However, it is
pertinent that scopolamine was reported previously to have low
potency (100 mg/kg) to reduce motion-induced emesis in Suncus
murinus (Ueno et al., 1988). In view of these anomalies, we
considered that the pharmacology of Suncus murinus histamine
and muscarinic receptors may be atypical and could explain
why mepyramine and scopolamine appeared less effective than
expected: the in vitro studies on the ileum provided some data to
support this hypothesis.
Histamine had mixed actions on Suncus murinus isolated
ilea segments; there was an initial transient relaxation followed
by a sustained contraction, which differs from effects observed
in other species, such as guinea pigs (for review see Parsons,
1982). The contractile action appeared independent of the
cholinergic system (resistant to atropine and hexamethonium),
but was partially dependent on enteric nerves, since tetrodotoxin
reduced the contractile response by 52%. Both mepyramine and
cetirizine behaved as low-potency, non-competitive antagonists,
with pKb values of 7.5 and 8.4, respectively. On rat and guinea
pig H1 receptors, both drugs are competitive antagonists, with
pA2 values of ∼9.6 and ∼9.4, respectively (Koo, 1983; Suhagia
et al., 2006). Conversely, scopolamine behaved as a competitive
antagonist, with a pA2 of 9.5, consistent with data on rat and
human tissues (Brown et al., 1980; Halim et al., 1981). This leads
us to conclude that Suncus murinus H1 receptors differ from
those in the rat, guinea, pig and human, whereas muscarinic
receptors appear broadly similar.
Taking the above into account, as well as considering the
potency of mepyramine and cetirizine from in vivo studies (Al
Suleimani et al., 2008), we selected doses of mepyramine and
scopolamine of 50 and 10 mg/kg, respectively; the choice of the
dose of mepyramine being 2.5 times higher than those used in
the original motion-induced emesis studies (Ueno et al., 1988).
Comparison of the data for scopolamine from in vivo studies in
rats (Morita et al., 1988; Yu et al., 2007) led us to select a dose
of 10 mg/kg, which we considered sufficient to block muscarinic
receptors (10 times lower than in the original studies) (Ueno
et al., 1988).
Attenuation of Motion-Induced Effects by
Blockade of Central H1 Receptors and
Muscarinic Receptors
One of themajor findings of the present study is thatmepyramine
was more effective than cetirizine in preventing motion-induced
emesis. This suggests that H1 receptors located centrally mediate
the anti-emetic effects of antihistamines. Indeed, mepyramine
was more active than scopolamine, but this advantage needs
to be considered against the backdrop of effects on behavior,
temperature homeostasis, and GMA. Mepyramine was the only
compound to cause a reduction in scratching behavior and a
shift from resting to lying flat, which may indicate sedation. This
may also explain why mepyramine appeared to increase inter-
retch interval, effectively increasing the duration of individual
episodes. During the recovery period, mepyramine appeared to
increase inspiratory time and tidal volume, which may or may
not be related to its action to cause sedation. Alternatively,
this pattern may be interpreted as “deep breathing,” and “deep
breathing” techniques are used to abate nausea and emesis inman
(Sang et al., 2003; Sites et al., 2014). Yet in our studies, it might
not be possible to interpret these data relative to mechanisms
controlling nausea, since scopolamine did not share the profile
and the situation is complicated further since antihistamines and
scopolamine have anxiolytic properties that could impact on the
respiratory pattern if it also had a component involving stress
(Rodgers and Cole, 1995; Raber, 2005).
It is pertinent that mepyramine was the only treatment
to decrease DF and cause marked hypothermia that may
have also contributed to its bradygastric action; these effects
persisted throughout testing and recovery. An examination of
the collective GMA data revealed that all treatments reduced the
percentage power of normogastria. Data from isolated murine
interstitial cell of Cajal (ICC), show histamine increases the
resting membrane potential but not the frequency of slow waves
(Kim et al., 2013) and muscarinic receptor agonists have positive
chronotropic effects on slow waves in vitro and in vivo in
a number of species (Sanders et al., 2006). No studies have
examined isolated ICCs from Suncus murinus, but our data
suggests that there may be a basal tone on ICC involving
histamine and acetylcholine although this requires clarification.
Novel Insights into Central Emetic
Mechanisms from c-Fos Studies
Our most disappointing finding was that provocative motion
did not elicit any detectable activation of neurons in the studied
regions of the brain. Our previous studies using Suncus murinus
have shown that stimuli inducing 6–20 episodes of emesis
(average from all studies ∼10 episodes) are associated with
significant increases of c-fos expression in the brainstem (NTS,
AP), hypothalamus and amygdala (Chan et al., 2013, 2014).
However, our motion stimulus, which produced ∼10 episodes
over 10 min, did not. There have only been two other studies
where motion-induced emesis has been studied in conjunction
with immunohistochemistry for c-fos. In the first study, c-fos
expression was readily observed in animals with ∼21 episodes
when animals were exposed for 30min (Ito et al., 2003). In
the follow up study comparing animals that readily vomited
to motion, with those selectively bred to be insensitive, c-fos
expression could still be observed in the animals that were less
response following the 30 min stimulus (Ito et al., 2005). One of
the major differences between our studies and those previously
published, therefore, is the duration of the stimulus, and not the
number of episodes (Chan et al., 2013, 2014). If this is indeed
the case, it is possible that the pattern of c-fos expression seen
following longer exposure times to motion does not exclusively
relate to emetic mechanisms alone and may include motion-
induced changes in blood flow, discomfort and stress or malaise
and/or nausea (See Ito et al., 2003, 2005; Yates et al., 2014).
Retrospectively, therefore, it may have been better to have used a
longer duration stimulus, although interpretation of data arising
from such studies should be made cautiously (see Harris, 1998,
for a review). Unfortunately, however, none of the previous
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studies used anti-emetics to qualify the c-fos expression patterns
to mechanisms of motion sickness.
Nonetheless, we did identify that mepyramine (1 h
pretreatment, with or without motion) could induce large
increases in c-fos expression in the AP, NTS MVe, VMH, DMH,
PLH, PVH, and Arc, independent of whether the animals
experienced emesis or not. This pattern of c-fos activation is
paradoxical, being more expected from treatments that induce
(e.g., cisplatin, exendin-4, resiniferatoxin), rather than those that
inhibit emesis; anti-emetics to date have been shown to only
decrease such increases (Andrews et al., 2000; De Jonghe and
Horn, 2009; Chan et al., 2013). Certainly, scopolamine did not
share this profile of activation and yet it was only slightly less
effective at inhibiting motion-induced emesis.
In order to propose a possible explanation for the pattern
of c-fos induced by mepyramine, we need to consider that
it had pharmacological effects different from cetirizine and
scopolamine (mepyramine caused changes in behavior that we
interpreted as inhibitory or sedative, and there was also clear
hypothermia and a reduced DF in the GMA recorded from the
gastric antrum). Clearly, there may have been other physiological
changes that our studies were not designed to detect (e.g., blood
pressure). Next, we need consider several aspects of histaminergic
pathways and signaling. The cell bodies of histaminergic neurons
are located in the posterior region of the lateral hypothalamus
(in the tuberomammillary nucleus) and send projections toward
other parts of the hypothalamus, cortex, hippocampus, amygdala
and also toward the brainstem (Karasawa et al., 2001), although
another major source of histamine in the brain is from mast
cells (Goldschmidt et al., 1985; Kaji et al., 1991); the relative
contribution of histamine in emetic mechanisms coming from
neurons vs. mast cells is not known (Lucot and Takeda, 1992).
H1 receptors are located in many brain areas, cerebral cortex,
limbic system, NTS, and dorsal motor nucleus of the vagus nerve
(Palacios et al., 1981; Martinez-Mir et al., 1990). Though Gq/11
proteins, these receptors are coupled to the phospholipase C,
which in turn induces calcium-dependent events and excitation
of target cells (Banu and Watanabe, 1999).
If we follow the previous discoveries made in Suncus
murinus and in cats, we may conclude that the brainstem
NTS and lateral reticular formation, including the ventrolateral
reticular formation, the inferior olive, and vestibular nuclei and
nucleus ambiguous are involved. Evidence from physiological
experiments indicates that NTS neurons respond to electrical
stimulation of the VIIIth cranial nerve which links labyrinthine
receptors to the NTS, relaying to the pattern generator
for emesis in the reticular formation (See Ito et al., 2003,
2005; Yates et al., 2014). Unfortunately, there have been no
studies where intracerebral administration of histamine receptor
antagonists have been made into any of these nuclei during
motion-induced emesis experimentation. However, it is thought
that during provocative motion, a neural mismatch signal
activates histaminergic neurons in the hypothalamus, and the
histaminergic descending pathway to potentially stimulate H1
receptors in the brainstem’s “emetic center” (Takeda et al., 1986;
Horii et al., 1993; Uno et al., 1997; Schmäl, 2013). Whilst the
precise role of neuron and mast cell sources of histamine are not
known, it is known that H1 receptors are densely located in the
NTS and DMNV, and also the vestibular nucleus; all areas are
behind the blood brain barrier. It is conceivable that receptors in
the brainstem are key to the anti-emetic mechanism of action of
the anti-histamines, particularly since our burst analysis showed
that only mepyramine altered emetic patterns. There is also good
evidence that histamine administered into the 4th ventricle is
more potent to induce emesis than following administration into
the lateral ventricle in dogs which tends to implicate brainstem
mechanisms; the latency to induce emesis is also shorter and
licking, tachypnoea, restlessness, was also observed (Bhargava
and Dixit, 1968); mepyramine given into the lateral ventricles
antagonized the emesis induced by histamine given via the
same route (Bhargava et al., 1976). Electrophysiologically, there
are studies showing that histamine can induce and enhance
spontaneous firing of neurons in the vestibular nucleus in rats,
effects that are reduced by mepyramine and the H2 receptor
antagonist, cimetidine. However, mepyramine alone did not
appear to have any effect to depolarize or hyperpolarize neurons,
or to change the frequency of spontaneous firing (Yu et al.,
2015). In another rat study, histamine reportedly induced firing
of neurons in the NTS, which was blocked by the H1 receptor
antagonist, triprolidine. However, triprolidine failed to induce
significant changes when tested alone (Poole et al., 2008).
Although our functional studies on isolated ileal segments
in Suncus revealed all of our compounds as antagonists,
antihistamines have been documented to possess inverse agonist
properties at H1 receptors, and mepyramine is a proven full
inverse agonist (Fitzsimons et al., 2004). Does this mean,
therefore, that there are constitutively active H1 receptors in the
brain that mepyramine can exert negative efficacy to transduce
c-fos? Histamine itself can trigger expression of c-fos through
PKCα, MEK-1, and MAP kinase (Megson et al., 2001), but 5-
HT2C receptors, which are also coupled to Gq/11 do in fact
increase c-fos expression in the brain following treatment with
inverse agonists (Navailles et al., 2013). Clearly, if this is also
the case for mepyramine, it would alter our concept of how
antihistamines are acting to reduce emesis and the possibility that
there are differences in constitutively active H1 receptors between
motion-sensitive and non-sensitive individuals. Constitutive
activity is related to receptor density and the level of G protein
expression and upregulation of H1 receptor expression levels has
been found in patients with allergic rhinitis (Dinh et al., 2005). It
may be that motion-sensitive individuals have a higher density of
H1 receptors in emetic circuits, and that these patients benefit the
most from the use of H1 anti-histamines. It is certainly difficult
to reconcile any hypothesis from our limited data, and there
is a possibility that the effects we have observed are secondary
to mepyramine to increase inhibition within emetic circuits.
However, this latter hypothesis is less likely, as antihistamines do
not have broad inhibitory effects.
Both brain penetrating H1 antihistamines and scopolamine
are noted to reduce motion-induced nausea in man (see
introduction), but our studies were designed to primarily
study emesis. The behavioral and physiological readouts that
we obtained therefore cannot be considered representative of
nausea alone. Nevertheless, we compared all the data to see if
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there was any evidence that mepyramine and scopolamine had
mechanisms in common that could reflect an ability to reduce
“nausea” (see Introduction); certainly nothing was evident from
the pattern of c-fos. The only variable, apart from emesis, that was
consistently modulated by both mepyramine and scopolamine
was on GMA where a common reduction in the % power of
bradygastria was seen. However, cetirizine also had the same
action and duringmotionmepyramine and scopolamine failed to
differentiate from cetirizine. It is possible that this pattern relates
to the action of the compounds directly on the ICCs themselves.
Studies therefore need to be conducted where the anti-emetics are
administered centrally, to avoid exposure on the ICC, permitting
a more confident interpretation of mechanisms relative to nausea
and emesis.
Conclusions and Perspectives
In conclusion, we have shown that mepyramine is more
effective than cetirizine in preventing motion-induced emesis,
indicating that centrally located H1 receptors are critically
involved. Mepyramine caused behavior indicative of sedation,
hypothermia, and a fall in DF in the GMA, whereas cetirizine
and themuscarinic receptor antagonists, scopolamine, which was
anti-emetic, did not. The effects of mepyramine on respiration
and inter-retch/vomit episodes are more difficult to ascribe
to the anti-emetic mechanism of action, and requires further
clarification. The ability of mepyramine to increase c-fos in the
brain to a pattern reminiscent of emetic challenges (but without
induction of emesis) provides an important new insight into
mechanisms involved in emesis control in general.
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Supplementary Figure 1 | Correlations of physiological parameters from
pre-screening study. (A) Episodes vs. respiratory rate during motion; (B) Episodes
vs. respiratory rate during recovery; (C) DF vs. core body temperature during
baseline; (D) DF vs. core body temperature during motion; (E) DF vs. core body
temperature during recovery. Data represents the mean ± s.e.m. of 40–52
animals.
Supplementary Figure 2 | Temperature difference between vomited and
no-vomited animals during baseline, motion and recovery in pre-screening study.
(A) Baseline; (B) Motion; (C) Recovery; (D) 1 temperature during motion. Data
represents the mean ± s.e.m. of 51 vomited animals and 7 non-vomited animals.
Significant differences are shown as ∗p < 0.05, ∗∗p < 0.01 (unpaired t-test).
Supplementary Figure 3 | Singularity spectra of time series of GMA that were
estimated by multifractal detrended fluctuation analysis (MFDFA). (A) The width of
singularity strength 1α of baseline, motion, and recovery during pre-screening
study; (B) Graphs represents f (α) vs. singularity strength α; (C) representative raw
traces of gastric slow waves from baseline, motion and recovery. Data represents
the mean ± s.e.m. of 40–52 animals.
Supplementary Table 1 | Effect of mepyramine (50 mg/kg), cetirizine (10 mg/kg),
and scopolamine (10 mg/kg) on the width of singularity strength 1α of GMA. Data
represents the mean ± s.e.m. of 6 animals.
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